Junjie Zhu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11350005/publications.pdf Version: 2024-02-01



Ιμνιμε Ζημ

#	Article	lF	CITATIONS
1	Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?. Seminars in Cancer Biology, 2022, 86, 1190-1206.	4.3	18
2	Alterations of Cytochrome P450–Mediated Drug Metabolism during Liver Repair and Regeneration after Acetaminophen-Induced Liver Injury in Mice. Drug Metabolism and Disposition, 2022, 50, 694-703.	1.7	11
3	Biomimetic Trachea Engineering via a Modular Ring Strategy Based on Boneâ€Marrow Stem Cells and Atelocollagen for Use in Extensive Tracheal Reconstruction. Advanced Materials, 2022, 34, e2106755.	11.1	28
4	Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma. Hepatology Communications, 2022, 6, 1123-1139.	2.0	5
5	The relationship between vascular endothelial growth factor expression and the risk of childhood nephroblastoma: systematic review and meta-analysis. Translational Pediatrics, 2022, 11, 375-384.	0.5	0
6	In the Absence of YAP, TAZ Contributes to Hepatocyte Adaptation in Chronic Cholestasis in Females. FASEB Journal, 2022, 36, .	0.2	0
7	Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 1038-1046.	1.8	17
8	Targeting Xenobiotic Nuclear Receptors PXR and CAR to Prevent Cobicistat Hepatotoxicity. Toxicological Sciences, 2021, 181, 58-67.	1.4	12
9	Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. Drug Metabolism and Disposition, 2021, 49, 679-682.	1.7	20
10	Compensatory hepatic adaptation accompanies permanent absence of intrahepatic biliary network due to YAP1 loss in liver progenitors. Cell Reports, 2021, 36, 109310.	2.9	17
11	Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis. Gastroenterology, 2021, 161, 271-286.e11.	0.6	28
12	Role of CYP2A6 in Methimazole Bioactivation and Hepatotoxicity. Chemical Research in Toxicology, 2021, 34, 2534-2539.	1.7	2
13	Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Science Advances, 2021, 7, eabj4226.	4.7	11
14	Impact of obese levels on the hepatic expression of nuclear receptors and drug-metabolizing enzymes in adult and offspring mice. Acta Pharmaceutica Sinica B, 2020, 10, 171-185.	5.7	14
15	Cell Type–Specific Roles of CD38 in the Interactions of Isoniazid with NAD ⁺ in the Liver. Drug Metabolism and Disposition, 2020, 48, 1372-1379.	1.7	4
16	Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease. Hepatology, 2020, 72, 2165-2181.	3.6	12
17	ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 38-43.	1.3	4
18	Acetaminophen-Induced Liver Injury Alters Expression and Activities of Cytochrome P450 Enzymes in an Age-Dependent Manner in Mouse Liver. Drug Metabolism and Disposition, 2020, 48, 326-336.	1.7	25

Јимјіе Ζни

#	Article	IF	CITATIONS
19	Enzymes and Pathways of Kavain Bioactivation and Biotransformation. Chemical Research in Toxicology, 2019, 32, 1335-1342.	1.7	4
20	The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria. Science Advances, 2019, 5, eaaw6127.	4.7	25
21	Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. Acta Biomaterialia, 2019, 90, 300-313.	4.1	50
22	Pregnane X receptor activation potentiates ritonavir hepatotoxicity. Journal of Clinical Investigation, 2019, 129, 2898-2903.	3.9	32
23	CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor. Biochemical Pharmacology, 2018, 158, 174-184.	2.0	6
24	Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation. Chemical Research in Toxicology, 2018, 31, 548-555.	1.7	23
25	Metabolism of KO143, an ABCG2 inhibitor. Drug Metabolism and Pharmacokinetics, 2017, 32, 193-200.	1.1	28
26	4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists. European Journal of Medicinal Chemistry, 2014, 82, 1-15.	2.6	25
27	Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold. European Journal of Medicinal Chemistry, 2013, 69, 55-68.	2.6	13
28	Design, Synthesis, and Structure–Activity Relationships of 3,4,5â€Trisubstituted 4,5â€Dihydroâ€1,2,4â€oxadiazoles as TGR5 Agonists. ChemMedChem, 2013, 8, 1210-1223.	1.6	23